7 varieties to get priority review!

On February 20, CDE released a batch of priority review and approval lists to be included, including 7 heavyweight drugs including ciprofol emulsion injection, naproxen sodium tablets, tacrolimus granules, apartamide tablets, inhaled nitric oxide, atizumab injection, odm-201, etc Among them, tacrolimus granules are included for children's drug use, and the manufacturer is Astaire Inhaled nitric oxide was included for reasons of rare disease and children's medication Pulmonary hypertension (PAH) is an incurable and life-threatening disease that occurs when the pulmonary artery that carries blood from the heart to the lungs narrows and blocks If the baby is born with this disease, it is called PPHN or neonatal pulmonary hypertension PPHN is characterized by continuous hypoxia and cyanosis, leading to life-threatening circulatory and respiratory failure In developed countries, nitric oxide (no) inhalation has become a routine treatment for PPHN At present, the treatment has not been approved in China Naproxen sodium tablets of Renfu pharmaceutical Janssen apatadine tablets Artelizumab injection